Covered recipient · General Payments record
FARAMARZ ALAV
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$3,419.07
- Reported across 189 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $459.72 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Pharmaceuticals, Inc | $146.19 | 1 |
| Novo Nordisk AS | $91.76 | 5 |
| Lilly USA, LLC | $88.50 | 3 |
| Exact Sciences Corporation | $36.69 | 2 |
| Amgen Inc. | $33.54 | 2 |
| Astellas Pharma US Inc | $32.83 | 1 |
| GlaxoSmithKline, LLC. | $16.67 | 1 |
| Acerta Pharma LLC | $13.54 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.22 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117186619 | CMS |
| Amgen Inc. | $18.32 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117186621 | CMS |
| Astellas Pharma US Inc | $32.83 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139382336 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.54 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104330670 | CMS |
| Exact Sciences Corporation | $13.70 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114572626 | CMS |
| Exact Sciences Corporation | $22.99 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114572630 | CMS |
| GlaxoSmithKline, LLC. | $16.67 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116597483 | CMS |
| Janssen Pharmaceuticals, Inc | $146.19 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077923963 | CMS |
| Lilly USA, LLC | $33.50 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136174718 | CMS |
| Lilly USA, LLC | $25.00 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136174720 | CMS |
| Lilly USA, LLC | $30.00 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134975504 | CMS |
| Novo Nordisk Inc | $20.28 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097096709 | CMS |
| Novo Nordisk Inc | $14.15 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097568154 | CMS |
| Novo Nordisk Inc | $14.10 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096819041 | CMS |
| Novo Nordisk Inc | $19.58 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096893501 | CMS |
| Novo Nordisk Inc | $23.65 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097112293 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.